DDInter1662 DDInter1628
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Sertraline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) regulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is regulated by {v} (Gene) LTK
LTK {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is regulated by {v} (Gene) CTCF
CTCF {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) downregulates {v} (Gene) ITGAE
ITGAE {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) regulates {v} (Gene) PRAF2
PRAF2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Sertraline {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Sertraline (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Sertraline (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Ruxolitinib (Compound)
Sertraline (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Sertraline (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) regulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Sertraline (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is regulated by LTK (Gene) and LTK (Gene) is bound by Ruxolitinib (Compound)
Sertraline (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is regulated by CTCF (Gene) and CTCF (Gene) is upregulated by Ruxolitinib (Compound)
Sertraline (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Sertraline (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) regulates PRAF2 (Gene) and PRAF2 (Gene) is downregulated by Ruxolitinib (Compound)
Sertraline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)